Glucose-Induced Cyclic Lipopeptides Resistance in Bacteria via ATP Maintenance through Enhanced Glycolysis

Wen-Bang Yu, Qian Pan, Bang-Ce Ye
boye@ecust.edu.cn

HIGHLIGHTS
Glucose induces the drug resistance to CLPs
CLPs significantly inhibit energy metabolism and result in ATP depletion
Glucose maintains the intracellular ATP level in CLP-treated bacteria

Yu et al., iScience 21, 135–144
November 22, 2019 © 2019
The Author(s).
https://doi.org/10.1016/j.isci.2019.10.009
Glucose-Induced Cyclic Lipopeptides Resistance in Bacteria via ATP Maintenance through Enhanced Glycolysis

Wen-Bang Yu,1,2,4 Qian Pan,1,4 and Bang-Ce Ye1,3,5,*

SUMMARY
Cyclic lipopeptide (CLP) antibiotics have a mechanism that causes membrane malfunction. Thus mechanisms of bacterial resistance to CLPs are thought to modify cell surfaces. However, we found that bacterial resistance to CLPs was strongly related to energy metabolism. Using polymyxin B (PB) as a model of CLPs, we showed that PB causes malfunction of respiration and serious depletion of ATP, contributing to PB-induced cell death and carbon starvation. Glucose addition could maintain the intracellular ATP level and reverse the carbon starvation response resulting from PB treatment. Another study revealed that glycolysis was stimulated by the presence of PB and glucose. The mechanism underlying glucose-enabled CLPs’ resistance suggests that glucose could maintain the ATP level in PB-treated bacteria by enhancing glycolysis. Similar results were observed in Staphylococcus aureus, where daptomycin resistance was enhanced by glucose. These findings provide insight into the mode of action of CLPs and resistance to these antibiotics.

INTRODUCTION
Antibiotics are useful for treating bacterial infections. However, the worldwide emergence of drug-resistant bacteria is a great threat to antibiotic efficacy. Cyclic lipopeptides (CLPs) produced by diverse groups of bacteria are receiving more and more attention because of their broad-spectrum activity against microorganisms, including multidrug-resistant pathogens (Baltz, 2009; Straus and Hancock, 2006). All CLPs are composed of a circular oligopeptide linked to a fatty acid chain. They also have a similar mode of action, which involves membrane integrity impairment and dissipation of membrane potential (Straus and Hancock, 2006). In recent years, studies have revealed that CLPs might have a second mode of action (Baltz, 2009; Hamamoto et al., 2015; Trimble et al., 2016; Xing et al., 2014). A recently identified CLP, lysozyme E, was shown to inhibit respiration in Staphylococcus aureus by directly interacting with menaquinone (Hamamoto et al., 2015). The well-studied daptomycin (DAP) could cause dissipation of membrane potential and cell death without damaging membrane integrity. Moreover, polymyxin B (PB) was found to inhibit NADH dehydrogenase (NDH) from the gram-positive bacterium M. smegmatis (Mogi et al., 2009).

DAP and PB are two important CLPs that have been used in medical treatment for decades. Unfortunately, pathogens resistant to DAP and PB have emerged (Miller et al., 2016). However, knowledge of the CLPs’ resistance mechanism is restricted to the modification of the cell wall, cell membrane, or outer membrane (Bayer et al., 2013; Fischer et al., 2011; Wosten et al., 2000). The dlt operon in S. aureus could reduce the negative charge of the cell surface and keep DAP away from the cell membrane (Bayer et al., 2013). MprF is a DAP-resistant protein responsible for lysylation of PG, which also reduces the negative charge of the cell surface in S. aureus (Bayer et al., 2013). Fischer et al. compared the transcriptomic and proteomic profiles of a DAP-resistant methicillin-resistant S. aureus strain with those of the DAP-sensitive strain (Fischer et al., 2011). Their results showed that many genes involved in cell wall metabolism were significantly up-regulated in the DAP-resistant isolate, indicating the important role of cell wall in DAP resistance (Fischer et al., 2011). PmrA-PmrB in Salmonella is a two-component system that responds to the cellular iron level, induces the expression of genes involved in outer membrane modification, and confers PB resistance (Wosten et al., 2000).

Glucose is a prior carbon source that can support rapid growth of microorganisms (Sonenshein, 2007). Several recent studies showed that glucose and other carbon sources such as mannitol, fructose, and glycerol could affect the antibiotic sensitivity of the microorganism by regulating the metabolic state. Allison et al. found that these carbon sources could activate the membrane potential of Escherichia coli persisters,
M. smegmatis

cells died before being reverted by glucose.

These results might indicate that PB resulted in a lower energy status of the cell and is activated by fructose metabolism or metabolism is repressed, whereas catabolism of glucose is activated by CcpA, which senses glucose transporters to glucose.

The results indicated that glucose induced bacterial resistance to PB by maintaining the intracellular ATP level and reverse the carbon starvation response resulting from treatment of PB. The results indicated that glucose induced bacterial resistance to PB by maintaining the intracellular ATP level in PB-treated bacteria through enhanced glycolysis. Similar results were also observed in S. aureus, where DAP resistance was enhanced by glucose. These findings demonstrated that the intracellular ATP level was important for the mode of action of CLPs, and they provide insight into bacterial resistance to these antibiotics.

To investigate the relationship between carbon metabolism and the action of CLPs, proteomic analysis was performed with B. subtilis cells treated with PB, PB plus glucose, or glucose. After applying a cutoff value of 1.2-fold change (p < 0.05), the expressions of 805, 594, and 478 proteins were found to be significantly changed after treatment by PB, PB plus glucose, or glucose, respectively (Figure S1 and Table S1). As shown in Figure 2, MalP and ManP were involved in mannose uptake, MtlA was involved in mannitol uptake, LevDE was involved in fructose uptake, GlpTK was involved in glycerol uptake, AcoL was involved in acetoin catabolism, RocG was involved in glutamate catabolism and the proteins SdhAB that compose the succinate dehydrogenase complex, AcsA was involved in acetate utilization, and GapB was involved in gluconeogenesis, and they were all significantly up-regulated in PB-treated B. subtilis (Figure 2). However, no change was observed in B. subtilis treated with PB plus glucose (Figure 2). Pgi, Pgk, Eno, FbaA, and Ldh were involved in the glycolysis pathway, and they were significantly down-regulated by PB treatment. None of them were down-regulated after treatment with PB plus glucose. In B. subtilis, alternative carbon acquisition or metabolism is repressed, whereas catabolism of glucose is activated by CcpA, which senses the energy status of the cell and is activated by fructose-1,6-bisphosphate (FBP) or high ATP concentrations (Ludwig et al., 2001; Sonenshein, 2007). These results might indicate that PB resulted in a lower energy status before being reverted by glucose.

To investigate the relationship between carbon metabolism and the action of CLPs, proteomic analysis was performed with B. subtilis cells treated with PB, PB plus glucose, or glucose. After applying a cutoff value of 1.2-fold change (p < 0.05), the expressions of 805, 594, and 478 proteins were found to be significantly changed after treatment by PB, PB plus glucose, or glucose, respectively (Figure S1 and Table S1). As shown in Figure 2, MalP and ManP were involved in mannose uptake, MtlA was involved in mannitol uptake, LevDE was involved in fructose uptake, GlpTK was involved in glycerol uptake, AcoL was involved in acetoin catabolism, RocG was involved in glutamate catabolism and the proteins SdhAB that compose the succinate dehydrogenase complex, AcsA was involved in acetate utilization, and GapB was involved in gluconeogenesis, and they were all significantly up-regulated in PB-treated B. subtilis (Figure 2). However, no change was observed in B. subtilis treated with PB plus glucose (Figure 2). Pgi, Pgk, Eno, FbaA, and Ldh were involved in the glycolysis pathway, and they were significantly down-regulated by PB treatment. None of them were down-regulated after treatment with PB plus glucose. In B. subtilis, alternative carbon acquisition or metabolism is repressed, whereas catabolism of glucose is activated by CcpA, which senses the energy status of the cell and is activated by fructose-1,6-bisphosphate (FBP) or high ATP concentrations (Ludwig et al., 2001; Sonenshein, 2007). These results might indicate that PB resulted in a lower energy status before being reverted by glucose.

The proteins involved in respiration are also shown in Figure 2. PB repressed cytochrome cca3 (CtaCDF), menaquinol-cytochrome c reductase (QcrABC), and cytochrome bd (CydA) expression, but it induced NADH-Q dehydrogenase (YjLD, renamed Ndh) and succinate dehydrogenase (SdhAB) expression. It seems that PB leads to respiratory malfunction and serious depletion of ATP, contributing to PB-induced cell death and an obvious carbon starvation response. The addition of glucose could maintain the intracellular ATP level and reverse the carbon starvation response resulting from treatment of PB. The results indicated that glucose induced bacterial resistance to PB by maintaining the intracellular ATP level in PB-treated bacteria through enhanced glycolysis. Similar results were also observed in S. aureus, where DAP resistance was enhanced by glucose. These findings demonstrated that the intracellular ATP level was important for the mode of action of CLPs, and they provide insight into bacterial resistance to these antibiotics.

RESULTS
Glucose-Induced Drug Resistance to CLPs
We previously studied the mode of action of CLPs on B. subtilis using transcriptome analysis, which revealed that CLPs caused significant carbon starvation (Yu et al., 2012). We wondered if the bactericidal activity of CLPs was related to carbon metabolism. Here, we investigated the effect of some carbon sources (20 mM glucose, fructose, glycerol, and arabinose) on the bactericidal activity of PB in B. subtilis (Figures 1A and B). B. subtilis cells incubated in Luria broth medium with or without carbon sources were treated with 50 μg/mL PB. As shown in Figures 1A and 1B, both glucose and fructose significantly enhanced drug resistance to PB in B. subtilis. Glycerol and arabinose had weaker effect on PB resistance in B. subtilis (Figure 1B).

To study if glucose-induced resistance is applicable to other CLPs, we tested the effect of glucose on B. subtilis’ resistance to DAP. As shown in Figure 1C, glucose also enhanced B. subtilis’ resistance to DAP. With increase in glucose concentrations, bacterial resistance to DAP increased. However, these results showed that higher concentration of glucose (15 mM) was needed to completely inhibit the activity of DAP with a concentration of 5 μg/mL (Figure 1C). This might be because the activity of DAP is more efficient than that of PB when treating B. subtilis. We also tested if glucose induced resistance to other cationic antimicrobial peptides (such as vancomycin [VAN]). However, with the presence of glucose, resistance of B. subtilis to VAN was not enhanced (Figure 1D).
significantly repressed. However, Ndh expression was less up-regulated, and CydA was significantly up-regulated. These observations indicated that glucose could revert the NADH/NAD⁺ increase and cause some degree of respiratory malfunction.

**PB Inhibited NADH Dehydrogenase and ATP Synthesis, Leading to ATP Depletion**

The proteomics results revealed an increase in the NADH/NAD⁺ ratio, and Mogi et al. reported that PB can inhibit NADH-Q dehydrogenase in *M. smegmatis*. We reasoned that PB might also inhibit respiratory NDH in *B. subtilis* (Mogi et al., 2009). To test this, *B. subtilis* cell membrane preparation was treated with or without PB in the presence of menaquinone and NADH. As shown in Figure 3, the decreasing velocity of NADH was much slower with PB, indicating that NDH enzyme activity was inhibited by PB (Figure 3A). The IC50 values of PB to NDH were determined to be 18.82 μg/mL. *B. subtilis* is a facultative anaerobe whose ATP was mainly supplied by aerobic respiration under aerobic conditions. Inhibition of respiratory NDH might inhibit ATP synthesis. Moreover, PB causes dissipation of PMF, which activates F0-F1 ATP synthetase (Maloney et al., 1974). This result suggested that PB might inhibit ATP synthesis in vivo. The intracellular ATP level in PB-treated bacteria was determined using the ATP-analyzing kit. We found that the ATP level decreased in PB-treated bacteria in a dose-dependent manner (Figure 3B). To examine if ATP depletion results in the bactericidal action of PB, *B. subtilis* was pretreated with 1 mM dicyclohexylcarbodiimide (DCCD), which is an inhibitor of F0-F1 ATP synthase. As shown in Figures 3C and 3D, *B. subtilis*...
pretreated with DCCD were more sensitive to PB, which is indicated by a faster OD600 drop and lower ATP level. These results indicated that PB caused ATP depletion and contributed to cell death.

**Glucose Maintained the Intracellular ATP Level in PB-Treated *B. subtilis***

Glucose is a key carbon source that supplies energy for bacterial growth (Sonenshein, 2007). This could keep the intracellular ATP level in PB-treated bacteria. To test this, the intracellular ATP levels were analyzed in the presence of PB, PB plus glucose, or glucose. As shown in Figure 4, ATP levels in PB-treated bacteria were much lower than that in the control. However, this was reverted by glucose, which increased the ATP level in the PB-treated bacteria to about 2-fold compared with control (Figure 4). It was noted that the ATP level in the PB plus glucose treatment was much lower than in the glucose only treatment, indicating that PB still inhibited ATP synthesis even in the presence of glucose.

In bacteria, glucose can generate ATP via glycolysis or the electron transport chain (ETC). To investigate if glucose enhanced ATP synthesis via ETC after PB treatment, we examined the PMF of the *B. subtilis* treated with PB or PB plus glucose. As shown in Figure S5A, the PMF of PB-treated bacteria was increased to some degree by glucose, but that was still lower than the PMF of the untreated bacteria. Fructose that enabled drug resistance had no effect on the PMF in PB-treated bacteria (Figure S5A). As glucose did not restore the PMF to the control level, we suggested that glucose might stimulate glycolysis to generate ATP in the

---

**Figure 2. Expression Levels of Proteins Involved in Carbon Metabolism and Aerobic Respiration of *B. subtilis* Treated with PB, PB Plus Glucose, or Glucose**

Three columns from left to right represent expression ratios of proteins in response to treatment of PB (blue), PB plus glucose (green), and glucose (yellow). Two dotted lines were used to indicate the cutoff value: red line (1.2-fold) and green line (0.83-fold).
presence of PB. To support this, we determined the intracellular metabolites (glucose, pyruvate, and acetate) of the glycolytic pathway to analyze glycolytic activity. As shown in Figures 5B–5D, the intracellular levels of these metabolites were significantly lower in the PB-treated *B. subtilis* than in the untreated ones, indicating that PB led to carbon source depletion and low glycolytic activity. However, the intracellular concentrations of glucose, pyruvate, and acetate were greatly increased in the PB treatment plus glucose, suggesting that glucose reverses carbon starvation and low glycolysis in the PB-treated bacteria. In the presence of PB, *B. subtilis* would uptake more glucose and increase the glycolytic pathway flux. These results showed that glucose induced bacterial resistance to PB by increasing intracellular ATP level via enhancement of glycolysis.

**Figure 3. PB Inhibited NADH Dehydrogenase and ATP Synthesis**

Three biological replicates were used for each assay. Data are represented as mean ± SD.

(A) Activity of membrane-bound NADH dehydrogenase after treatment of different concentrations of PB (20, 30, 40, 50, 60, 70 μg/mL). The absorbance level of NADH in the treatments of PB (0, 20, 30, 40, 50 μg/mL) was significantly different.

(B) In vivo ATP levels of *B. subtilis* after treatment of different concentrations of PB (20, 30, 40, 50 μg/mL). The concentration of ATP in each sample was significantly different.

(C) Growth curve of *B. subtilis* after treatment of PB and PB plus DCCD.

(D) In vivo ATP levels of *B. subtilis* after treatment of PB and PB plus DCCD. *p < 0.05, **p < 0.01 by one-way ANOVA t test.

**Figure 4. Determination of Intracellular ATP Levels of *B. subtilis* with No Treatment and Treatment of PB, Glucose (Glc), and PB Plus Glc**

Data are represented as mean ± SD. The ATP concentrations of the samples with no treatment and treatment of PB were significantly different (*p < 0.05).
Glycolysis Is the Key Pathway that Enables PB Resistance in *B. subtilis*

To confirm that glycolysis enables PB resistance, the bacteria were treated with cysteine, an inhibitor of pyruvate kinase, to inhibit glycolysis flux (Kedryna et al., 1983). As shown in Figure 6A, in the presence of cysteine, glucose could not induce resistance to PB in *B. subtilis*. We also tested the effect of the tricarboxylic acid (TCA) cycle on glucose-enabled drug resistance by treating *B. subtilis* with a high concentration of malonic acid (20 mM), an inhibitor of succinate dehydrogenase, to inhibit TCA flux (Lu et al., 2018) (Figure 6C). Malonic acid did not eliminate glucose-enabled drug resistance, but the live percentage of the PB plus glucose plus malonic acid treatment was slower than the PB plus glucose treatment. These observations demonstrated that glycolysis was essential in glucose-enabled drug resistance, but the TCA cycle was not essential. Glucose catabolism could generate NADH, which is oxidized by ETC, contributes to PMF, and activates F0-F1 ATP synthase to generate ATP. Next, we investigated the effect of F0-F1 ATP synthase on glucose-enabled drug resistance by treating *B. subtilis* with DCCD, an inhibitor of F0-F1 ATP synthase (Rao et al., 2008). With a DCCD supplement, we found that PB resistance could be eliminated by 2 mM DCCD. This result indicated that F0-F1 ATP synthase might also contribute to glucose-enabled drug resistance (Figure 6B).

**Figure 5. Analysis of PMF and Glycolysis Metabolites**

Three biological replicates were used for each assay. Data are represented as mean ± SD.

(A) PMF of *B. subtilis* with no treatment and treatment of PB plus no metabolite (PB), glucose (PB + Glc), arabinose (PB + Ara), glycerol (PB + Gly), and fructose (PB + Fru). The PMF of the samples with no treatment and treatment of PB were significantly different.

(B) Intracellular glucose levels of *B. subtilis* with no treatment and treatment of PB, glucose (Glc), and PB plus glucose (PB + Glc). The glucose concentrations of the samples with no treatment and treatment of PB were significantly different.

(C) Intracellular levels of pyruvate (Pyr) of *B. subtilis* with no treatment and treatment of PB, glucose (Glc), and PB plus glucose (PB + Glc). The pyruvate concentrations of the samples with no treatment and treatment of PB were significantly different.

(D) Intracellular levels of acetate of *B. subtilis* with no treatment and treatment of PB, glucose (Glc), and PB plus glucose (PB + Glc). The acetate concentrations of the samples with no treatment and treatment of PB were significantly different.

*p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA t test.
Glucose Also Induced Bacterial Resistance to CLPs in Staphylococcus aureus

After showing that glucose induces resistance to CLPs in B. subtilis, we investigated if the phenomenon is applicable to S. aureus. As S. aureus is not sensitive to PB, we treated S. aureus with DAP (5 \( \mu \)g/mL). The results showed that DAP also resulted in serious ATP depletion leading to cell death in S. aureus (Figures 7A and 7B). With the addition of glucose, the ATP level was maintained and the killing activity of DAP was inhibited (Figures 7A and 7B). Moreover, we observed that glucose-induced drug resistance to CLPs in S. aureus was eliminated by cysteine (Figure 7A). Collectively, these observations demonstrated that glucose induces bacterial resistance to CLPs in S. aureus through the same mechanism as it does in B. subtilis.

**DISCUSSION**

Previous knowledge about the mechanism of CLPs’ resistance in bacteria was restricted to cell surface modifications. However, we found that glucose could enable bacterial resistance to CLPs. To understand how glucose enables bacterial resistance to CLPs, we re-investigated CLPs’ action using PB as a model CLP. The CLPs’ mechanism was supposed to destroy lipid bilayer membrane integrity and cause dissipation of membrane potential (Straus and Hancock, 2006). However, several studies showed that the destruction of membrane integrity was not the sole killing mechanism in the action of CLPs (Baltz, 2009; Hamamoto et al., 2015; Mogi et al., 2009; Trimble et al., 2016; Xing et al., 2014). That is because cellular processes such as cell division, cell wall component synthesis, and energetics are affected by membrane integrity (Baltz, 2009; Straus and Hancock, 2006). In a recent study by Mogi et al., PB was found to be a potent inhibitor of membrane-bound NDH from M. smegmatis, indicating that PB might disturb the energetic status (Mogi et al., 2009). Here, we investigated the energy status of PB-treated bacteria. We found that PB would cause significant ATP depletion in B. subtilis. This contributed to its killing action, indicating that energetics is a PB target. Furthermore, we found that glucose could maintain the intracellular ATP level in PB-treated bacteria. We suggested that glucose enables bacterial PB resistance by maintaining the ATP level.

To scrutinize how glucose maintains the ATP level in PB-treated bacteria, we used proteomic analysis to investigate the metabolic status of bacteria after PB treatment. The results revealed that PB inhibited membrane-bound NDH in B. subtilis and caused down-regulation of respiration complexes, indicating that PB caused respiratory malfunction. PB treatment also caused PMF dissipation. These were the reasons why PB caused ATP depletion. PB treatment caused a significant response of carbon starvation. First, many proteins involved in transport and catabolism of alternative carbon sources were up-regulated (Ludwig et al., 2001; Sonenshein, 2007). Second, PB treatment also caused significant decrease in the levels of carbon metabolites in vivo, including glucose, pyruvate, and acetate. Thus, this could be explained by the fact that PB leads to low energy status and so more carbon sources were catabolized to maintain the energy status for survival. As a result, in vivo carbon metabolites were exhausted. However, this carbon starvation state was reverted by glucose. With a supplement of glucose, the bacteria could achieve enough carbon...
sources for survival. Owing to inhibition of respiration, the bacteria might maintain the energy status by enhancing glycolysis. To confirm this hypothesis, we compared the levels of the glycolytic metabolites, including glucose, pyruvate, and acetate in PB/glucose- and glucose-treated bacteria. The results showed that levels of the glucose, pyruvate, and acetate are much higher in PB/glucose-treated bacteria, demonstrating that glycolysis was enhanced by PB.

We also explored the role of the TCA cycle and F0-F1 ATP synthase in glucose-enabled drug resistance. The drug resistance could be eliminated by a high concentration of DCCD but not by malonic acid. This indicated that F0-F1 ATP synthase might partially contribute to PB resistance, but TCA does not. It seemed that glycolysis alone could not sustain survival of PB-treated bacteria in the glucose test concentration range. However, DCCD might have an additional effect, which causes dissipation of PMF in *B. subtilis* (Calamita et al., 2001). As glucose had no significant effect on restoration of the PMF, DCCD may cause a further dissipation of PMF, which may lead to cell lysis in *B. subtilis* (Calamita et al., 2001).

Inhibition of NDH will restrict NADH/NAD⁺ turnover leading to NAD⁺ limitation in vivo (Gyan et al., 2006). As NAD⁺ is the main oxidant in the cell, restoration of the NAD⁺ pool makes NADH turnover a top priority compared with ATP synthesis (Yang et al., 2018). As seen in the proteomic results, NDH expression was 2-fold up-regulated in PB treatment but 1.3-fold up-regulated in PB plus glucose treatment. This indicated that glucose might revert the increase in NADH/NAD⁺. Here, we noted that NadA and NadB involved in NAD⁺ synthesis were significantly up-regulated (2.2-fold and 3.2-fold, respectively) with glucose supplement, but these two proteins were down-regulated (0.51-fold and 0.60-fold, respectively) with PB treatment. Thus, it was possible that glucose increased the NAD⁺ pool to revert the increase in NADH/NAD⁺. However, this hypothesis needs to be further confirmed.

This work demonstrated that bacterial sensitivity to CLPs is strongly related to energy metabolism. The relation between bacterial resistance to antibiotics and energy metabolism is also observed elsewhere (Cheng et al., 2018; Liu et al., 2019; Su et al., 2018). Herein, we showed that CLPs could disturb ATP synthesis and cause cell death, but glucose can maintain the ATP level by enhancing glycolysis and enabling drug resistance (Figure 8). This study provides insight into the mode of action of CLPs and bacterial resistance mechanisms to CLPs.

**Limitations of the Study**
In this study, the molecular mechanism underlying ATP depletion induced by CLP antibiotics remains unclear.

**METHODS**
All methods can be found in the accompanying Transparent Methods supplemental file.
Figure 8. The Mechanism Underlying Glucose-Induced Bacterial Resistance to CLPs
CLPs inhibit aerobic respiration and cause PMF dissipation, leading to ATP depletion and contributing to cell death. Glucose maintains the ATP level by enhancing glycolysis and maintaining cell survival.

SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.isci.2019.10.009.

ACKNOWLEDGMENTS
This study was supported by grants from the National Natural Science Foundation of China (31730004) and the National Key Research and Development Program of China (2018YFA0900404).

AUTHOR CONTRIBUTIONS
Conceptualization, W.-B.Y., Q.P., and B.-C.Y.; Methodology, Q.P.; Resources, B.-C.Y.; Formal Analysis, W.-B.Y. and Q.P.; Writing – Original Draft, W.-B.Y.; Writing – Review & Editing, W.-B.Y., Q.P., and B.-C.Y.; Supervision, B.-C.Y.; Funding Acquisition, B.-C.Y.

DECLARATION OF INTERESTS
The authors declare no competing interests.

Received: March 1, 2019
Revised: June 20, 2019
Accepted: October 1, 2019
Published: November 22, 2019

REFERENCES
Allison, K.R., Brynildsen, M.P., and Collins, J.J. (2011). Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473, 216–220.

Baltz, R.H. (2009). Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol. 13, 144–151.

Bayer, A.S., Schneider, T., and Sahl, H.G. (2013). Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann. N. Y Acad. Sci. 1277, 139–158.

Calamita, H.G., Ehringer, W.D., Koch, A.L., and Doyle, R.J. (2001). Evidence that the cell wall of Bacillus subtilis is protonated during respiration. Proc. Natl. Acad. Sci. U S A 98, 15260–15263.

Cheng, Z.X., Yang, M.J., Peng, B., Peng, X.X., Lin, X.M., and Li, H. (2018). The depressed central carbon and energy metabolisms is associated to the acquisition of levofloxacin resistance in Vibrio alginolyticus. J. Proteomics 181, 83–91.

Fischer, A., Yang, S.J., Bayer, A.S., Vaezadeh, A.R., Herzig, S., Stenz, L., Girard, M., Sakoulas, G., Scherl, A., Yeaman, M.R., et al. (2011). Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J. Antimicrob. Chemother. 66, 1696–1711.

Geng, H., Zuber, P., and Nakano, M.M. (2007). Regulation of respiratory genes by ResD-ResE signal transduction system in Bacillus subtilis. Methods Enzymol. 422, 448–464.

Gyan, S., Shiohira, Y., Sato, I., Takeuchi, M., and Sato, T. (2006). Regulatory loop between redox sensing of the NADH/NAD(+)* ratio by ResD (YdiH)
and oxidation of NADH by NADH dehydrogenase Ndh in Bacillus subtilis. J. Bacteriol. 188, 7062–7071.

Hamamoto, H., Urai, M., Ishii, K., Yasukawa, J., Paudel, A., Murai, M., Kaji, T., Kuranaga, T., Hamase, K., Katsu, T., et al. (2015). Lysocin E is a new antibiotic that targets menaquinone in the bacterial membrane. Nat. Chem. Biol. 11, 127–U168.

Kedryna, T., Guminska, M., and Marchut, E. (1983). The inhibitory effect of L-cysteine and its derivatives on glycolysis in Ehrlich ascites tumour cells. Biochim. Biophys. Acta 763, 64–71.

Liu, S.R., Peng, X.X., and Li, H. (2019). Metabolic mechanism of ceftazidime resistance in Vibrio alginolyticus. Infect. Drug Resist. 12, 417–429.

Lu, Q., Zhao, Y., Gao, X.T., Wu, J.Q., Zhou, H.X., Tang, P.F., Wei, Q.B., and Wei, Z.M. (2018). Effect of tricarboxylic acid cycle regulator on carbon retention and organic component transformation during food waste composting. Bioresour. Technol. 256, 128–136.

Ludwig, H., Homuth, G., Schmalisch, M., Dyka, F.M., Hecker, M., and Stülke, J. (2001). Transcription of glycolytic genes and operons in Bacillus subtilis: evidence for the presence of multiple levels of control of the gapA operon. Mol. Microbiol. 41, 409–422.

Maloney, P.C., Kashket, E.R., and Wilson, T.H. (1974). A proton motive force drives ATP synthesis in bacteria. Proc. Natl. Acad. Sci. U S A 71, 3896–3900.

Miller, W.R., Bayer, A.S., and Arias, C.A. (2016). Mechanism of action and resistance to daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb. Perspect. Med. 6, a026997.

Mogi, T., Murase, Y., Mori, M., Shiomi, K., Omura, S., Paranagama, M.P., and Kita, K. (2009). Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate:quinone oxidoreductase from the gram-positive bacterium Mycobacterium smegmatis. J. Biochem. 146, 491–499.

Peng, B., Su, Y.B., Li, H., Han, Y., Guo, C., Tian, Y.M., and Peng, X.X. (2015). Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell Metab. 21, 249–262.

Rao, S.P.S., Alonso, S., Rand, L., Dick, T., and Pethe, K. (2008). The proton motive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U S A 105, 11945–11950.

Sonenshein, A.L. (2007). Control of key metabolic intersections in Bacillus subtilis. Nat. Rev. Microbiol. 5, 917–927.

Yu, W.B., Yin, C.Y., Zhou, Y., and Ye, B.C. (2012). Prediction of the mechanism of action of fusaricidin on Bacillus subtilis. PLoS One 7, e50003.

Su, Y.B., Peng, B., Li, H., Cheng, Z.X., Zhang, T.T., Zhu, J.X., Li, D., Li, M.Y., Ye, J.Z., Du, C.C., et al. (2018). Pyruvate cycle increases aminoglycoside efficacy and provides respiratory energy in bacteria. Proc. Natl. Acad. Sci. U S A 115, E1578–E1587.

Trimble, M.J., Milner, P., Kolar, M., and Hancock, R.E. (2016). Polymyxin: alternative mechanisms of action and resistance. Cold Spring Harb Perspect. Med. 6, a025288.

Wosten, M.M.S.M., Kox, L.F.F., Chamnongpol, S., Soncini, F.C., and Groisman, E.A. (2000). A signal transduction system that responds to extracellular iron. Cell 103, 113–125.

Xing, Y.H., Wang, W., Dai, S.Q., Liu, T.Y., Tan, J.J., Qu, G.L., Li, Y.X., Ling, Y., Liu, G., Fu, X.Q., et al. (2014). Daptomycin exerts rapid bactericidal activity against Bacillus anthracis without disrupting membrane integrity. Acta Pharmacol. Sin. 35, 211–218.

Yang, J., Zeng, Z.H., Yang, M.J., Cheng, Z.X., Peng, X.X., and Li, H. (2018). NaCl promotes antibiotic resistance by reducing redox states in Vibrio alginolyticus. Environ. Microbiol. 20, 4022–4036.
Supplemental Information

Glucose-Induced Cyclic Lipopeptides
Resistance in Bacteria via ATP Maintenance through Enhanced Glycolysis

Wen-Bang Yu, Qian Pan, and Bang-Ce Ye
Supplemental Figures

Figure S1. Numbers of differentially expressing proteins (P-value < 0.05) in treatments of glucose, PB plus glucose and glucose, respectively. Related to Figure 2.

Expression of 805 (379 proteins were down-regulated and 426 proteins were up-regulated), 594 (296 proteins were down-regulated and 298 proteins were up-regulated), and 478 (254 proteins were down-regulated and 224 proteins were up-regulated) proteins were found to be significantly changed after treatment by PB, PB plus glucose, or glucose, respectively.
**Transparent Methods**

**Bacterial strains, materials, and growth conditions**

*Bacillus subtilis* ATCC21616, *Staphylococcus aureus* ATCC12600 were firstly grown in glass flasks with the Luria-Bertani (LB) medium at 37 °C and 220 rpm. When the OD<sub>600</sub> of culture reach 0.3, the culture was split into 50 ml centrifuge tubes for adding polymyxin B (50 µg/ml), daptomycin (5 µg/ml), vancomycin (50 µg/ml), glucose (5-20 mM), fructose (20 mM), arabinose (20 mM), glycerol (20 mM), inhibitor et al. The final volume in each tube is 3ml. The same amount of bacteria culture was collected for ATP and metabolite detection. All carbon source, inhibitor and PB were purchased from Sigma Aldrich (St. Louis, MO, USA). Antibiotics were filtered with a 0.22 mm pore size hydrophilic PVDF membrane. Luria-Bertani (LB) were sterilized by autoclaving at 121 °C for 20 min. *Bacillus subtilis* ATCC21616 were grown to reach 1.0 of OD value for cell membrane preparation.

**Screening of carbon source**

*Bacillus subtilis* ATCC21616, *Staphylococcus aureus* ATCC12600 were firstly grown in glass flasks with the Luria-Bertani (LB) medium at 37 °C and 220 rpm. When the OD<sub>600</sub> of culture reach 0.3, the culture was split into 50 ml centrifuge tubes for adding polymyxin B (50 µg/ml), daptomycin (5 µg/ml), vancomycin (50 µg/ml), glucose (5-20 mM), fructose (20 mM), arabinose (20 mM), glycerol (20 mM), inhibitor et al. The final volume in each tube is 3ml. The same amount of bacteria culture was collected for ATP and metabolite detection. All carbon source, inhibitor and PB were purchased from Sigma Aldrich (St. Louis, MO, USA). Antibiotics were filtered with a 0.22 mm pore size hydrophilic PVDF membrane. Luria-Bertani (LB) were sterilized by autoclaving at 121 °C for 20 min. *Bacillus subtilis* ATCC21616 were grown to reach 1.0 of OD value for cell membrane preparation.

**Preparation of Bacillus subtilis membranes**

After reaching an OD<sub>600</sub> of 1.0, *Bacillus subtilis* ATCC21616 cells were collected using centrifugation at 3,500 r.p.m. for 30 min at 4 °C and washed twice using buffer solution containing 30 mM Tris–HCl and 10 mM Na-EDTA (pH 7.5). Cells were resuspended with 30 mM Tris–HCl, 10 mM Na-EDTA (pH 7.5), and protease inhibitor cocktail. The strains were lysed using high pressure at 13–14 MPa and centrifuged at 12,000 g for 15 min at 4 °C. Membranes were recovered from the supernatant using centrifugation at 150,000 g for 60 min at 4 °C and resuspended with 30 mM Tris–HCl (pH 7.5).

**Detection of NADH dehydrogenase activities**

NADH dehydrogenase activity assays were started using 10 mg/ml membranes, 200 mM NADH, 100 mM Q1, 50 mM Tris–HCl (pH 7.5), and 0.05% Tween 20. In the real-time monitoring of the enzymatic reaction, measurements of absorbance at 340 nm were acquired every 30 s for 10 min. For inhibition studies, the reaction mixture was
preincubated with polymyxin B (0, 20, 30, 40, 50, 75, 100 µg/ml) for 10 min. The
decreased values of absorbance were simulated using GraphPad Prism 5 (GraphPad
Software, Inc., La Jolla, CA) to get the 50% inhibitory concentration (IC50) of
polymyxin B.

**ATP level determination**

ATP detection kit was purchased from Beyotime Biotechnology (Shanghai, China). The
kit is based on firefly luciferase which uses ATP to catalyze luciferin to produce
fluorescence. When firefly luciferase and luciferin are both in excess, fluorescent
production is proportional to the concentration of ATP. The same amounts of bacteria
(10⁸ cells) were lysed in ice water mixture for 15 min by ATP detection lysis buffer to
release ATP. The fluorescence value was measured using the microplate reader
SynergyTM Mx (Bio-Tek Instruments, Winooski, VT) after adding ATP detection
reagent.

**Determination of glucose and organic acid levels**

The glucose detection kit was purchased from Sigma Aldrich (St. Louis, MO, USA).
First, ATP phosphorylates glucose via hexokinase. In the presence of oxidation type
nicotinamide adenine dinucleotide (NAD⁺), glucose-6-phosphate was phosphorylated
to produce 6-phosphoric acid-gluconic acid by glucose-6-phosphate dehydrogenase
(G6PDH). In the oxidation reaction, the increased absorption value of 340 nm is
directly proportional to the glucose concentration. The same amounts of bacteria (10⁸
cells) were lysed in ice water mixture for 15 min by glucose detection lysis buffer to
release glucose. The absorption value was measured using the microplate reader
SynergyTM Mx (Bio-Tek Instruments, Winooski, VT) after adding the glucose assay
reagent.

For determination of organic acids (pyruvate and acetate), 10⁹ cells were collected.
Metabolites from the cell pellets were extracted with 200 µl 5% HClO₄ in an ice bath
for 15 min. After centrifugation at 10000 g for 5 min, the supernatant was neutralized
with a K₂CO₃ solution, and the KClO₄ precipitate was removed by centrifugation.
Subsequently, the levels of organic acids were determined by High Performance Liquid
Chromatography. HPLC condition was 0.013 M H₂SO₄ at a flow rate of 1.0 mL/min
and 40 °C. UV spectra were acquired at 210 nm.

**Proteomic analysis**

The aim of this project was to use an integrated approach involving TMT labeling and
LC-MS/MS to quantify the dynamic changes of the whole proteome of *B. subtilis*. The
general work flow is indicated as follows: protein extraction, trypsin digestion, TMT
labeling, HPLC fractionation, LC-MS/MS analysis, database search, and bioinformatics analysis.

Sample was first grinded by liquid nitrogen, then the cell powder was transferred to 5
mL centrifuge tube and sonicated three times on ice using a high intensity ultrasonic processor (Scientz) in lysis buffer (8 M urea, 2 mM EDTA, 10 mM DTT, and 1% Protease Inhibitor Cocktail III). The remaining debris was removed by centrifugation at 20,000 g at 4 °C for 10 min. Finally, the protein was precipitated with cold 15% TCA for 2 h at −20 °C. After centrifugation at 4 °C for 10 min, the supernatant was discarded. The remaining precipitate was washed with cold acetone three times. The protein was re-dissolved in buffer (8 M urea, 100 mM TEAB, pH 8.0) and the protein concentration was determined with 2-D Quant kit according to the manufacturer’s instructions. After trypsin digestion, peptides were desalted using the Strata X C18 SPE column (Phenomenex) and vacuum-dried. Peptides were reconstituted in 0.5 M TEAB and processed according to the manufacturer’s protocol for 6-plex TMT kit.

The sample was fractionated using high pH reverse-phase HPLC using Agilent 300Extend C18 column (5 μm particles, 4.6 mm ID, 250 mm length). Briefly, peptides were separated with a gradient of 2% to 60% acetonitrile in 10 mM ammonium bicarbonate pH 10 over 80 min into 80 fractions. The peptides were combined into 18 fractions and dried by vacuum centrifuging.

Peptides were dissolved in 0.1% FA, directly loaded onto a reversed-phase pre-column (Acclaim PepMap 100, Thermo Scientific). Peptide separation was performed using a reversed-phase analytical column (Acclaim PepMap RSLC, Thermo Scientific). The gradient was comprised of an increase from 6% to 22% solvent B (0.1% FA in 98% ACN) over 26 min, 22% to 35% in 8 min and climbing to 80% in 3 min then holding at 80% for the last 3 min, all at a constant flow rate of 350 nl/min on an EASY-nLC 1000 UPLC system. The resulting peptides were analyzed by Q ExactiveTM plus hybrid quadrupole-Orbitrap mass spectrometer (ThermoFisher Scientific).

The peptides were subjected to NSI source followed by tandem mass spectrometry (MS/MS) in Q ExactiveTM plus (Thermo) coupled online to the UPLC. Intact peptides were detected in the Orbitrap at a resolution of 70,000. Peptides were selected for MS/MS using an NCE setting of 30. Ion fragments were detected in the Orbitrap at a resolution of 17,500. A data-dependent procedure that alternated between one MS scan followed by 20 MS/MS scans was applied for the top 20 precursor ions above a threshold ion count of 10000 in the MS survey scan with 30.0s dynamic exclusion. The electrospray voltage applied was 2.0 kV. Automatic gain control (AGC) was used to prevent overfilling of the orbitrap; 5E4 ions were accumulated for generation of MS/MS spectra. For MS scans, the m/z scan range was 350 to 1800. Fixed first mass was set as 100 m/z.

The resulting MS/MS data were processed using Mascot search engine (v.2.3.0). Tandem mass spectra were searched against Uniprot Bacillus Subtilis (strain 168) database. Trypsin/P was specified as cleavage enzyme allowing up to 2 missing cleavages. Mass error was set to 10 ppm for precursor ions and 0.02 Da for fragmentations. Carbamidomethyl on Cys were specified as fixed modifications, and
oxidation on Met was specified as variable modifications. For protein quantification method, TMT-6-plex was selected in Mascot. FDR was adjusted to < 1% and peptide ion score was set ≥ 20.